Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PsyPal psilocybin therapy for psychological distress in palliative patients
2023-510488-36-01Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2 trial of psilocybin in major depressive disorder (MDD) and distress (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in depressive symptoms. Planned start Jun 2025; status: authorised.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)distress
Beyond the preview
Go deeper on 2023-510488-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510488-36-01.